drugset / Trial / NCT00673361
Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma
NaSingle-groupOpen-labelTreatment
Summary
This research study is testing the "chemo-switch" strategy in melanoma, using biochemotherapy initially to shrink tumors and then switching to daily low-dose chemotherapy (temozolomide) together with sorafenib. The purpose of this study is to find out what effects (good and bad) biochemotherapy followed by temozolomide plus sorafenib have on melanoma.
Timeline
- Start
- 2007-03
- Primary completion
- 2009-01
- Completion
- 2009-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 20 mg/m2 | Intravenous |
| Subject | IL (interleukin)-2 | Unknown | 4.5 unknown | Intravenous |
| Subject | Interferon (IFN) alpha | Unknown | 5 unknown | Subcutaneous |
| Subject | Sorafenib | Small molecule | 400 mg | Oral |
| Subject | Temozolomide | Small molecule | 75 mg/m2 | Oral |
| Subject | Vinblastine | Small molecule | 1.5 mg/m2 | Intravenous |